模型引导的药物开发方法支持纳武利尤单抗(Opdivo)4周(Q4W)给药方案跨多适应症获批:监管视角
美国FDA基于药代动力学建模与模拟、剂量/暴露-效应关系及临床安全性数据,批准纳武利尤单抗480 mg静脉注射每4周(Q4W)方案用于多数已获批适应症。预测显示480 mg Q4W的稳态平均浓度较3 mg/kg Q2W高5.2%,谷浓度低15.6%,疗效与安全性相似。
要点
- 480 mg Q4W方案经FDA批准用于纳武利尤单抗多数已获批适应症。
- 预测480 mg Q4W稳态Cavg较3 mg/kg Q2W高5.2%,Ctrough低15.6%。
- 预测各适应症疗效与3 mg/kg Q2W相比不太可能受损。
核心结论
- 基于广泛临床经验的模型引导分析提示,480 mg Q4W方案的获益-风险特征与已批准的3 mg/kg Q2W方案相当,为无临床疗效数据情况下批准该新方案提供了监管依据。
研究设计与样本
- 基于药代动力学建模与模拟、疗效与安全性剂量/暴露-效应关系及480 mg Q4W临床安全性数据的监管分析。
- 在21项临床试验的4166例多种实体瘤和血液肿瘤患者中预测480 mg Q4W的药代动力学暴露。
- 对所有FDA批准的纳武利尤单抗适应症进行暴露-效应分析以预测480 mg Q4W的安全性和疗效。
主要发现
- 总体人群中,480 mg i.v. Q4W的稳态Cavg几何均值较3 mg/kg i.v. Q2W高5.2%,Ctrough低15.6%。
- 480 mg Q4W模拟的浓度-时间过程低于临床试验中研究的10 mg/kg i.v. Q2W的中位浓度。
- 480 mg Q4W预测的不良事件概率与3 mg/kg Q2W方案观察到的相似。
- 肾细胞癌患者中Q2W与Q3W给药方案的疗效结果相似。
- 各适应症的预测疗效提示480 mg Q4W与3 mg/kg Q2W观察到的疗效相比不太可能受损。
关键数值与推荐
- 480 mg i.v. Q4W稳态Cavg几何均值较3 mg/kg i.v. Q2W高5.2%。
- 480 mg i.v. Q4W稳态Ctrough几何均值较3 mg/kg i.v. Q2W低15.6%。
- 480 mg Q4W模拟浓度低于10 mg/kg i.v. Q2W的中位浓度。
临床怎么用
- 原文基于模型引导分析支持480 mg Q4W方案获批,未给出具体临床使用推荐。
局限性
- 新剂量方案480 mg Q4W缺乏临床疗效数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A nivolumab dosage regimen of 480 mg intravenously (i.v.) every 4 weeks (Q4W) was approved by FDA for the majority of the approved indications for nivolumab. METHODS: The proposed new dosage regimen was supported by pharmacokinetic modeling and simulation, dose/exposure-response relationships for efficacy and safety in the indicated patient populations, and the clinical safety data with the 480 mg Q4W dosage regimen. Pharmacokinetic exposures achieved with 480 mg Q4W were predicted for 4166 patients in 21 clinical studies with various types of solid and hematological tumors. Exposure-response analyses were conducted to predict 480 mg Q4W safety and efficacy across all FDA-approved indications for nivolumab. RESULTS: For the overall population, the geometric mean exposure achieved with 480 mg i.v. Q4W was 5.2% higher for steady state Cavg and 15.6% lower for Ctrough than those with 3 mg/kg i.v. Q2W, the approved dosage regimen. The simulated concentration-time course achieved with 480 mg Q4W regimen was below the median concentration achieved with 10 mg/kg i.v. Q2W that was also studied in clinical trials. The predicted probability of adverse events was similar between 480 mg Q4W and that observed with the 3 mg/kg Q2W regimen. Efficacy results were found to be similar between Q2W and Q3W dosage regimens in patients with renal cell carcinoma. The predicted efficacy for each indication suggested that the efficacy with 480 mg Q4W is unlikely to be compromised compared with that observed with 3 mg/kg Q2W. CONCLUSIONS: The model-informed analyses of predicted exposure, efficacy and safety based on data from extensive clinical experience with nivolumab suggest that the benefit-risk profile of 480 mg Q4W regimen is comparable to the approved 3 mg/kg Q2W regimen, thus providing the regulatory basis for the approval of 480 mg Q4W regimen in the absence of clinical efficacy data with this new dosage regimen.
引用
- Bi Y, Liu J, Furmanski B, et al. Model-informed drug development approach supporting approval of the 4-week (Q4W) dosing schedule for nivolumab (Opdivo) across multiple indications: a regulatory perspective. Ann Oncol. 2019. PMID: 30715147. doi:10.1093/annonc/mdz037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。